GSK3 polypeptides

The invention provides truncated GSK 3 polypeptides capable of crystallization, including GSK 3 alpha and GSK 3 beta polypeptides, and use of these polypeptides to identify and optimize GSK 3 inhibitors. Also provided are GSK 3 polypeptides having at least one substituted amino acid that differs fro...

Full description

Saved in:
Bibliographic Details
Main Authors NGUYEN STEVE H, MEDINA-SELBY ANGELICA, HARRISON STEPHEN D, CALDERON-CACIA MARIA, COIT DORIS G, ZHONG ZIYANG, FANG ERIC Y, HALL JOHN A
Format Patent
LanguageEnglish
Published 31.07.2008
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
DERIVATIVES THEREOF
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
NUCLEIC ACIDS
NUCLEOSIDES
NUCLEOTIDES
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
SUGARS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The invention provides truncated GSK 3 polypeptides capable of crystallization, including GSK 3 alpha and GSK 3 beta polypeptides, and use of these polypeptides to identify and optimize GSK 3 inhibitors. Also provided are GSK 3 polypeptides having at least one substituted amino acid that differs from wild-type GSK 3 , wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK 3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.
Bibliography:Application Number: US20080074543